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Background:
Hepatitis C is a global health issue with approximately 3% of the worlds’ population estimated to be infected
with the hepatitis C virus (HCV) Inefficiencies in treatment has led to development of direct-acting antivirals
(DAAs) that specifically target HCV proteins involved in the virus’s life cycle1. One of the major concerns arising
from the use of the DAAs is the emergence of resistance-associated variants (RAVs) that affect the efficacy of
the drugs. RAVs are generally associated with a fitness cost and the use of ultra-deep pyrosequencing
technology has shown that in most treatment naïve subjects low frequency circulating strains carry RAVs2.
The aim of the study was to investigate i) the clinical relevance of low frequency RAVs; ii) the persistence of
RAVs and iii) compensatory mutations in a subset of subjects who had failed boceprevir (SCH 503034; protease
inhibitor).
Figure 6: Multiple RAV combinations on single strains at VF.
Discussion
Despite the emergence of new promising drugs that specifically target HCV, the development of novel effective
antiviral therapies for hepatitis C is still facing the challenging issue of the rapid selection of viral variants bearing
drug resistance mutations. This study used 454-PrimerID to mitigate RT-PCR errors and issues surrounding re-
sampling of template molecules in the PCR process and yielded data to accurately quantify the number of unique
viral sequences being studied in subjects that have failed treatment with one of the DAAs, boceprevir. Specifically,
the study shows the clinical relevance of RAVs below the detection threshold of Sanger sequencing in clinical
outcome. This data supports the previous observation that HCV strains with RAVs at lower than the level
detectable by sanger-based sequencing can reduce drug sensitivity4. Given the success of this technique in
studying viral quasi-species before, during and after VF in these subjects, 454-PrimerID sequencing should
become the standard approach by which to perform temporal 454-sequence studies.
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Subjects
Subjects were enrolled in the long-term follow-up study P-05063 of previous treatment with boceprevir.
(ClinicalTrials.gov Identifier: NCT00689390). These subjects all had detectable RAVs at the virologic failure (VF)
time-point based on Sanger sequencing. Twelve subjects had three time-points available: at baseline before the
commencement of boceprevir treatment; at VF; and follow-up (median 830.5 days from VF).
Table 1 Comparison of RAV frequencies in longitudinal samples by population (Sanger) sequencing and 454-PrimerID.
Results
















1 copy 1 x 10
12 copies100% PCR efficiency  x 40 cycles
100 copies 1.6 x 1012 copies80% PCR efficiency x 40 cycles
Figure 1 Reverse transcription with Primer ID. NS3 target binding Site (TBS), TAG 3bp Subject tag, 
PID=N8  65,536 unique primers, Generic PBS 2 x 17 bp primer binding sites




Figure 2: PCR amplification induced 
artifacts
Conclusions
1) Ultra-deep sequencing identifies clinically relevant low frequency RAVs in circulating quasispecies at levels not
detectable using Sanger sequencing
2) PCR amplification induced artefacts are eliminated using the primer ID methodology and analysis pipeline
3) Specifically, the study shows the clinical relevance of RAVs below the detection threshold of Sanger sequencing
in clinical outcome.
4) This data supports the previous observation that HCV strains with RAVs at lower than the level detectable by
sanger-based sequencing can reduce drug sensitivity.
5) In the majority of subjects, RAVs were detected at high levels at VF but this did not predict which RAVs would
be present after 1-2 years of follow-up
6) The low prevalence of naturally occurring drug-resistance mutants suggests that resistant variants are not as
fit as wild type viruses. However, some strains that harbor RAVs can overcome that replication deficiency most
likely via the support of compensatory mutations.
Http://iiid.Murdoch.edu.au
Figure 4: Correlation between variation observed from PrimerID
analysis (X-axis) and normal variant analysis without bar-coding














Figure 5: Percentage difference between variant
detected by bar-coding PrimerID method and without
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Methods
The primer design was based on the Primer ID format as described in Jabara et al. 20113, in which a random
eight nucleotide tag (‘barcode’) is inserted after the target sequence with the 5’ addition of a non-specific
sequence to allow amplification by PCR (Figure 1). Ideally, each cDNA template should be synthesized with a
unique barcode tag, this was facilitated by keeping the starting viral copies (<20,000) much lower than the
number of primer ID’s (65,536 IDs) allowing an accurate estimation of viral species in the sample pool and the
elimination of PCR induced artefacts in the analysis pipeline (Figure 2).
Workflow
 454-Primer ID technology improves the detection of clinically relevant low frequency
RAVs compared to sanger sequencing (Table 1).
 Low frequency viral strains harboring RAVs can persist for up to two years post-
treatment failure.
 Strains carrying multiple RAVs are common in breakthrough viruses.
 Evidence for mutation networks within NS3 protease and putative
compensatory mutations ( Fig 6)
Eleven sites known to be associated with boceprevir drug resistance were screened: V36A/M, R155K/Q/T,
Q41R, F43S, T54A/S, V55A, Q80K/R, S138T, A156S/T/V, V158I, D168A/T/V and V170A/T. Each site was
studied in order to evaluate the frequency of RAVs within the viral quasispecies.
The cDNA template was amplified by nested PCR of the NS3 protease region. Amplicons were sequenced
using both Sanger population sequencing and Next generation sequencing on the Roche 454 GS FLX+
Platform with XLR70 Titanium Chemistry (Figure 3).
Figure 3: Sequencing Workflow
